Baseline patient characteristics
| Anakinra + MTX (n = 250) | Placebo + MTX (n = 251) | |
|---|---|---|
| MTX, methotrexate; RF, rheumatoid factor; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis. | ||
| *Includes Asian, Japanese, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Aborigine, and other. | ||
| Female sex (%) | 79 | 75 |
| Age (years), mean | 56 | 57 |
| Ethnicity: | ||
| Caucasian (%) | 86 | 87 |
| African American (%) | 5 | 6 |
| Latino (%) | 6 | 4 |
| Other* (%) | 3 | 2 |
| Duration of RA (years), mean | 11 | 10 |
| Weight (kg), mean | 82 | 80 |
| RF positivity (%) | 76 | 78 |
| NSAID use (%) | 76 | 77 |
| Corticosteroid use (%) | 53 | 52 |
| MTX dose (mg/week), mean | 16 | 16 |
| MTX dose (mg/week, %): | ||
| <12.5 | 18 | 18 |
| 12.5–14.9 | 12 | 12 |
| ⩾15 | 70 | 70 |